➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Baxter
Merck
AstraZeneca
Mallinckrodt

Last Updated: May 25, 2020

DrugPatentWatch Database Preview

ANJESO Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Anjeso, and what generic alternatives are available?

Anjeso is a drug marketed by Baudax and is included in one NDA. There are four patents protecting this drug.

This drug has thirty patent family members in eleven countries.

The generic ingredient in ANJESO is meloxicam. There are twenty-two drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

US ANDA Litigation and Generic Entry Outlook for Anjeso

A generic version of ANJESO was approved as meloxicam by BRECKENRIDGE PHARM on July 19th, 2006.

  Start Trial

Summary for ANJESO
International Patents:30
US Patents:4
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for ANJESO
DailyMed Link:ANJESO at DailyMed
Drug patent expirations by year for ANJESO
Drug Prices for ANJESO

See drug prices for ANJESO

US Patents and Regulatory Information for ANJESO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Baxter
Merck
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.